Encodia
Andrew ElBardissi, MD, is a Partner at Deerfield Management since January 2017 and holds several board member positions at various companies, including Medical Microinstruments, Inc., Aurion Biotech, Bitteroot, Adela Bio, Encodia, Inc., Endologix LLC, Sema4, Reprieve Cardiovascular, and Element Science, Inc. Andrew possesses advanced educational credentials, including an MBA from Harvard Business School, an MPH in Quantitative Methods from Harvard T.H. Chan School of Public Health, and a Doctor of Medicine degree from Mayo Clinic Alix School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Encodia
4 followers
Encodia is a privately held biotechnology company bringing the power of sequencing to proteomics. The company's patented ProteoCode technology enables highly scalable protein analysis via an accessible and easy-to-use benchtop instrument. Tools employing Encodia’s ProteoCode technology will drive new biological understanding with impact in data-driven drug discovery and development, new high complexity diagnostics, and beyond.